This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.3390/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q93187209
rdf:type
wikibase:Item
schema:description
im April 2020 veröffentlichter wissenschaftlicher Artikel wetenschappelijk artikel наукова стаття, опублікована 21 квітня 2020 artículu científicu espublizáu n'abril de 2020 scientific article published on 21 April 2020
p:P577
wds:Q93187209-AA93381B-8413-4F38-81E2-14C43B9C2430
wdt:P577
2020-04-21T00:00:00Z
rdfs:label
Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
skos:prefLabel
Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
schema:name
Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
p:P50
wds:Q93187209-BC6644AF-E14D-4683-924D-D54B8AE607EF wds:Q93187209-830F9EB1-8B44-48EB-87E0-103B383CFEBE wds:Q93187209-8D0DADB5-0873-4CC9-9241-F4C7676D570A wds:Q93187209-E97871E9-7341-43CD-8852-BC8F5F281500 wds:Q93187209-E5852118-E5F3-479F-A1D9-8E97D527400E wds:Q93187209-F114D1C1-6E6A-4354-8A8B-254E43131DC8 wds:Q93187209-1C7E2FC8-ED18-4343-9FA6-B12ADDA1FEBB wds:Q93187209-14AA1019-797C-477D-98DD-2A20E77CED44 wds:Q93187209-12467F26-CA81-441D-A7D5-79422AAE79A9 wds:Q93187209-7C3239BC-E1BE-40E8-A931-5BF39CFBADF2 wds:Q93187209-6F94A33C-10ED-4A35-92EA-3F33BB555E84 wds:Q93187209-81DE7486-75FD-46B1-A834-86A78636C2EE wds:Q93187209-62A220E2-D9C8-4C83-8C19-D6DDE1E810B3 wds:Q93187209-697BF11E-D8DC-4E91-AB36-6DF2BE94211B wds:Q93187209-66D933E2-10DB-4ED5-9471-6B7D64F2E553
wdt:P50
wd:Q87717191 wd:Q79610970 wd:Q114401016 wd:Q39183342 wd:Q91579535 wd:Q93187203 wd:Q114401015 wd:Q88917814 wd:Q89376278 wd:Q38326061 wd:Q84779638 wd:Q57036090 wd:Q80245819 wd:Q39190002 wd:Q93187201
p:P1476
wds:Q93187209-880F2EAF-679D-4324-87C6-0B9AB6424051
wdt:P1476
Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
p:P31
wds:Q93187209-8133B0F7-4F0F-4536-BF2D-544394EF71A4
wdt:P31
wd:Q13442814
p:P921
wds:Q93187209-5585E12E-6125-450B-8FB5-FA6CD521D3B1
wdt:P921
wd:Q1620196
p:P698
wds:Q93187209-DF31C881-D14B-4E5C-922A-439AAA395B2A
wdtn:P698
n12:32326199
wdt:P698
32326199
p:P1433
wds:Q93187209-8CB9320D-2DA6-45D3-BA38-F83718B53FAB
wdt:P1433
wd:Q27722963
p:P433
wds:Q93187209-FE07BB5B-4A29-4F17-BD42-81580F11730E
p:P478
wds:Q93187209-0E7F2A23-7CD3-4F77-B686-906064784B5E
wdt:P433
4
wdt:P478
12
p:P356
wds:Q93187209-65946DF9-860D-4B60-BC5D-3081A6DCAD0F
wdtn:P356
n11:CANCERS12041017
wdt:P356
10.3390/CANCERS12041017
p:P275
wds:Q93187209-ba061244-2252-40bf-8efd-268f0a1ecb8b
p:P6216
wds:Q93187209-513e111e-2d48-4a72-b344-5c516159c62e
wdt:P275
wd:Q20007257
wdt:P6216
wd:Q50423863
p:P932
wds:Q93187209-A807AD26-C151-450D-B3FD-9D980BF4A21A
wdt:P932
7226418